Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem®

Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem®

DUBLIN, Sept. 11, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc. (JAZZ) today announced that a new patent related to Xyrem® (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today. The new patent, number 8,262,650, will be submitted for listing in the FDA's Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book).

In addition to the new patent, nine other U.S. patents have been issued related to Xyrem's stable and microbially resistant formulation, its manufacturing process and its method of use, including its restricted distribution system. The new patent, which will expire in December 2019, will be the eighth patent referencing Xyrem to be listed in the Orange Book.  The listed patents expire at various times from 2019 to 2024.

"Continually enhancing the patient and provider experience with Xyrem is an important strategic priority for our company, and our intellectual property related to Xyrem has been integral to ensuring the safe and effective use of sodium oxybate for the past 10 years," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

Xyrem (sodium oxybate) oral solution is the only product approved by the United States Food and Drug Administration for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. For further information see www.jazzpharmaceuticals.com.

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.